Rapid Tests Market Set to Hit USD 19.3 Billion by 2033

Rapid diagnostic testing has moved from a pandemic-era necessity to a permanent pillar of modern healthcare. From emergency rooms diagnosing sepsis in minutes to parents checking their child for flu at home, rapid tests are redefining how quickly clinical decisions get made. Here's a closer look at where this market stands today and where it's headed.

Market Overview & Projections

The global rapid tests market is on a steady growth trajectory. Valued at USD 12.8 billion in 2025, the market is estimated to reach USD 13.1 billion in 2026 and is projected to climb to USD 19.3 billion by 2033, growing at a CAGR of 5.3% from 2026 to 2033.

This growth is being driven by several converging forces:

• A growing geriatric population more susceptible to respiratory and chronic infections
• Rising target disease burden, including respiratory tract infections, sepsis, and antibiotic-resistant infections
• Increasing adoption of self-testing and point-of-care (POC) products, a trend accelerated during COVID-19 and now firmly embedded in consumer healthcare habits

Regionally, North America led the market with a 44.4% revenue share in 2025, thanks to high disease incidence, strong healthcare spending, and early access to advanced diagnostic products. Asia Pacific, meanwhile, is expected to be the fastest-growing region through 2033, fueled by expanding healthcare infrastructure, rising public health investment, and growing home-testing and pharmacy-based diagnostics in urban centers.

Respiratory illnesses continue to be a major demand driver. Conditions like respiratory syncytial virus (RSV) cause an estimated 33 million acute lower respiratory infections annually in children under five worldwide, while influenza and RSV together account for a significant share of seasonal rapid-test demand. Beyond respiratory disease, rapid tests are steadily expanding into sepsis screening, antimicrobial resistance surveillance, and infectious disease programs in underserved regions — widening the market's addressable base well beyond its traditional core.

Leading Technologies

Two technology categories dominate the rapid tests landscape, each serving distinct clinical needs.

Immunoassay technology held the largest share of the market at 47.3% in 2025. Lateral flow and chromatographic immunoassays — used in products like BinaxNOW and Sofia RSV FIA — detect antigens in as little as 15–30 minutes. Their affordability and simplicity relative to molecular platforms make them the backbone of high-volume testing in hospitals, clinics, and at-home kits alike.

Molecular diagnostics, however, is the technology to watch. It's projected to be the fastest-growing segment through the forecast period, driven by FDA-approved RT-PCR platforms such as BioFire's FilmArray and Cepheid's GeneXpert. Newer multiplex panels — capable of detecting 15+ pathogens in a single run in under 90 minutes — are pushing molecular testing beyond specialized labs and into point-of-care settings, improving both speed and diagnostic accuracy for syndromic conditions like gastrointestinal and CNS infections.

Innovation isn't stopping there. Companies are increasingly layering AI, machine learning, and microfluidics into their platforms to boost sensitivity, enable multiplexing, and simplify use — a shift that's making advanced diagnostics viable in non-traditional settings, including the home.

Curious about the underlying data behind these numbers? Download a free sample of the Rapid Tests Market report

Common Types of Rapid Tests

Rapid tests today span a wide range of clinical applications, but a few categories stand out:

• Respiratory tract infection tests — the single largest application segment at 30.0% share in 2025, covering influenza, RSV, streptococcus, and COVID-19 detection. These tests are central to reducing unnecessary antibiotic prescriptions by quickly distinguishing viral from bacterial causes.
• Sepsis tests — an area of rapid innovation, with new molecular assays enabling detection of bacterial and fungal pathogens directly from blood, in some cases cutting mortality and hospital stays significantly when deployed early.
• Antibiotic-resistant infection tests — the fastest-growing application segment, reflecting the global urgency around antimicrobial resistance and diagnostic-driven antibiotic stewardship.
• Sexually transmitted infection (STI) and gastrointestinal infection tests — growing steadily as decentralized and at-home testing expands access to diagnosis outside traditional clinical settings.

On the product side, consumables dominate with a 63.7% revenue share, reflecting high testing volumes and recurring demand, while instruments are gaining ground as hospitals and labs invest in automated, multiplex molecular platforms. By end use, hospitals and clinics lead at 38.4% share, but at-home testing is the fastest-growing segment, underscoring the broader shift toward decentralized, consumer-driven diagnostics.

Diagnostic companies — from Abbott and Roche to bioMérieux and Thermo Fisher — are actively repositioning through product launches, partnerships, and portfolio expansion to capture share in this evolving landscape.

Want to understand how the key players are positioning themselves for this shift? Explore key player strategies in the full report